Post-transplant management for heart recipients requires balancing the prevention of acute rejection with the mitigation of chronic immunosuppression side effects, such as nephrotoxicity, infection, and malignancy. Standardized protocols often evolve toward individualized care, particularly as patients age and immune systems weaken. Surveillance strategies are currently shifting from traditional, biopsy-heavy methods toward non-invasive biomarkers like donor-derived cell-free DNA, although clinical trial data is needed to secure broader insurance coverage and standardization. Long-term complications like cardiac allograft vasculopathy remain significant, necessitating aggressive risk factor modification and ongoing monitoring. For young patients facing end-stage graft failure, re-transplantation offers a potential second chance, though organ scarcity and comorbidities complicate candidacy. Ultimately, the transition from hyper-vigilant early post-operative care to long-term independence requires clear communication and patient flexibility to adapt to emerging medical advancements.
Sign in to continue reading, translating and more.
Continue
